Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 18 results
Author
Title
[
Type
]
Year
Filters:
Author
is
Sandborn, William J
[Clear All Filters]
Journal Article
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
Panaccione R
,
Danese S
,
Sandborn WJ
,
O'Brien CD
,
Zhou Y
,
Zhang H
,
Adedokun OJ
,
Tikhonov I
,
Targan S
,
Abreu MT
et al.
. 2020.
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
.
Aliment Pharmacol Ther. 52(11-12):1658-1675.
Faleck DM
,
Winters A
,
Chablaney S
,
Shashi P
,
Meserve J
,
Weiss A
,
Aniwan S
,
Koliani-Pace JL
,
Kochhar G
,
Boland BS
et al.
. 2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Battat R
,
Duijvestein M
,
Casteele NVande
,
Singh S
,
Dulai PS
,
Valasek MA
,
Mimms L
,
McFarland J
,
Hester KD
,
Renshaw M
et al.
. 2018.
Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.
.
Clin Gastroenterol Hepatol.
Sandborn WJ
,
Feagan BG
,
Fedorak RN
,
Scherl E
,
Fleisher MR
,
Katz S
,
Johanns J
,
Blank M
,
Rutgeerts P
. 2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
.
Gastroenterology. 135(4):1130-41.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Ma C
,
Sedano R
,
Almradi A
,
Casteele NVande
,
Parker CE
,
Guizzetti L
,
Schaeffer DF
,
Riddell RH
,
Pai RK
,
Battat R
et al.
. 2021.
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.
.
Gastroenterology. 160(7):2291-2302.
Ma C
,
Battat R
,
Dulai PS
,
Parker CE
,
Sandborn WJ
,
Feagan BG
,
Jairath V
. 2019.
Innovations in Oral Therapies for Inflammatory Bowel Disease.
.
Drugs. 79(12):1321-1335.
Dulai PS
,
Battat R
,
Barsky M
,
Nguyen NH
,
Ma C
,
Narula N
,
Mosli M
,
Casteele NVande
,
Boland BS
,
Prokop L
et al.
. 2020.
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
.
Am J Gastroenterol. 115(6):885-894.
Battat R
,
Duijvestein M
,
Guizzetti L
,
Choudhary D
,
Boland BS
,
Dulai PS
,
Parker CE
,
Nguyen TM
,
Singh S
,
Casteele NVande
et al.
. 2019.
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
.
Am J Gastroenterol. 114(5):733-745.
Sandborn WJ
,
Feagan BG
,
Loftus EV
,
Peyrin-Biroulet L
,
Van Assche G
,
D'Haens G
,
Schreiber S
,
Colombel J-F
,
Lewis JD
,
Ghosh S
et al.
. 2020.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
.
Gastroenterology. 158(8):2123-2138.e8.
Yang E
,
Panaccione N
,
Whitmire N
,
Dulai PS
,
Casteele NVande
,
Singh S
,
Boland BS
,
Collins A
,
Sandborn WJ
,
Panaccione R
et al.
. 2020.
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
.
Aliment Pharmacol Ther. 51(11):1031-1038.
Shen B
,
Kochhar GS
,
Kariv R
,
Liu X
,
Navaneethan U
,
Rubin DT
,
Cross RK
,
Sugita A
,
D'Hoore A
,
Schairer J
et al.
. 2021.
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.
.
Lancet Gastroenterol Hepatol. 6(10):826-849.
Dulai PS
,
Singh S
,
Casteele NVande
,
Meserve J
,
Winters A
,
Chablaney S
,
Aniwan S
,
Shashi P
,
Kochhar G
,
Weiss A
et al.
. 2020.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Battat R
,
Dulai PS
,
Casteele NVande
,
Evans E
,
Hester KD
,
Webster E
,
Jain A
,
Proudfoot JA
,
Mairalles A
,
Neill J
et al.
. 2019.
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
.
Inflamm Bowel Dis. 25(2):410-420.
Battat R
,
Hemperly A
,
Truong S
,
Whitmire N
,
Boland BS
,
Dulai PS
,
Holmer AK
,
Nguyen NH
,
Singh S
,
Casteele NVande
et al.
. 2021.
Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 19(3):511-518.e6.
Battat R
,
Sandborn WJ
. 2021.
Advances in the Comprehensive Management of Postoperative Crohn's Disease.
.
Clin Gastroenterol Hepatol.